Who Supplies Ustekinumab? Top Manufacturers & Their Global Buyers
India accounts for a significant share of global Ustekinumab exports, with 23+ registered manufacturers shipping to buyers across 10+ countries — yet a handful of companies dominate the shipments. GNH INDIA PHARMACEUTICALS LIMITED holds the largest share at 15.4% (export value: $196.0K). Close behind, BIOCON BIOLOGICS INDIA LIMITED (12.6%, $160.7K). NIVIRA EXPORTS (10.8%, $137.3K). The Sankey diagram below maps every supplier's customer flow in detail. All figures are drawn from Indian Customs (DGFT) shipping bill records.
🏭 Market Analysis: Top Suppliers & Customer Networks
Comprehensive supplier network intelligence dashboard
Who Supplies Ustekinumab? Top Manufacturers & Their Buyers
Flow of Ustekinumab from leading Indian exporters to their key global customers
Supplier-Customer Network Analysis
Top Suppliers → Customer Networks
Ustekinumab Supplier Network — Key Market Intelligence
The Ustekinumab export market from India is led by GNH INDIA PHARMACEUTICALS LIMITED, which alone commands a 15.4% share, shipping $196.0K worth of product across 33 shipments. The second-largest exporter, BIOCON BIOLOGICS INDIA LIMITED, contributes $160.7K (12.6%) to the overall market. Combined, the top two suppliers alone account for 28.0% of all Ustekinumab exports, indicating a relatively concentrated supply base.
Across all 23 tracked manufacturers, the total Ustekinumab export value stands at $1.3M from 276 shipments. The market average shipment value is $4.6K. The single largest buyer relationship in terms of trade value is AS PER INVOICE BRAZIL, receiving $112.2K worth of product.
The combined buyer network spans 16 named purchasing companies, including SHIMA HIROMI, XXSHIXXO IXX, Naoko Shioji, XXITHXXS MXXICAXXDEV, TO THE CONCERN PERSON and 11 others. These buyers represent pharmaceutical manufacturers, distributors, hospital procurement groups, and generic drug producers operating across multiple continents.
Market Analysis: Top Suppliers & Their Customer Networks
1GNH INDIA PHARMACEUTICALS LIMITED
GNH INDIA PHARMACEUTICALS LIMITED is the first-largest Ustekinumab exporter from India, with a market share of 15.4% and a total export value of $196.0K across 33 shipments. Their average shipment value of $5.9K is above the market average of $4.6K, suggesting premium or bulk contract pricing.
GNH INDIA PHARMACEUTICALS LIMITED serves 5 named buyers in our database. TO THE ORDER, is the dominant customer, accounting for 54.4% of this supplier's tracked business. Top customers include:
• TO THE ORDER, — $106.7K across 18 shipments (54.4% of this supplier's total exports)
• TO THE ORDER, — $62.5K across 11 shipments (31.9% of this supplier's total exports)
• TO THE ORDER, — $9.1K across 2 shipments (4.6% of this supplier's total exports)
• TO THE ORDER, — $8.9K across 1 shipments (4.5% of this supplier's total exports)
• TO THE ORDER, — $8.9K across 1 shipments (4.5% of this supplier's total exports)
Key Insight: GNH INDIA PHARMACEUTICALS LIMITED's per-shipment value of $5.9K is 29% above the market average of $4.6K, consistent with large-order contracts or value-added formulations.
2BIOCON BIOLOGICS INDIA LIMITED
BIOCON BIOLOGICS INDIA LIMITED is the second-largest Ustekinumab exporter from India, with a market share of 12.6% and a total export value of $160.7K across 5 shipments. Their average shipment value of $32.1K is above the market average of $4.6K, suggesting premium or bulk contract pricing.
BIOCON BIOLOGICS INDIA LIMITED serves 4 named buyers in our database. SHIMA HIROMI is the dominant customer, accounting for 65.8% of this supplier's tracked business. Top customers include:
• SHIMA HIROMI — $105.7K across 3 shipments (65.8% of this supplier's total exports)
• XXSHIXXO IXX — $27.5K across 1 shipments (17.1% of this supplier's total exports)
• Naoko Shioji — $27.4K across 1 shipments (17.1% of this supplier's total exports)
• XXITHXXS MXXICAXXDEV — $8 across 0 shipments (0.0% of this supplier's total exports)
Key Insight: BIOCON BIOLOGICS INDIA LIMITED's per-shipment value of $32.1K is 597% above the market average of $4.6K, consistent with large-order contracts or value-added formulations.
3NIVIRA EXPORTS
NIVIRA EXPORTS is the third-largest Ustekinumab exporter from India, with a market share of 10.8% and a total export value of $137.3K across 61 shipments. Their average shipment value of $2.3K is below the market average of $4.6K, reflecting a high-volume, competitive pricing strategy.
NIVIRA EXPORTS serves 5 named buyers in our database. Business is spread across multiple buyers, reducing single-customer dependency. Top customers include:
• TO THE CONCERN PERSON — $56.2K across 25 shipments (41.0% of this supplier's total exports)
• NEUSA ALVES DA SILVA — $29.7K across 13 shipments (21.7% of this supplier's total exports)
• ISIS DE OLIVEIRA MELO FELTRIN — $24.1K across 11 shipments (17.5% of this supplier's total exports)
• FABIO ROSA VACCARI — $15.0K across 7 shipments (10.9% of this supplier's total exports)
• SARAH CRISTINA DIAS RIBEIRO — $12.2K across 5 shipments (8.9% of this supplier's total exports)
Key Insight: NIVIRA EXPORTS operates with high shipment frequency (61 shipments) at a per-shipment value of $2.3K, indicating a broad distribution network with many smaller, regular orders.
4VAMA LIFECARE PRIVATE LIMITED
VAMA LIFECARE PRIVATE LIMITED is the fourth-largest Ustekinumab exporter from India, with a market share of 9.9% and a total export value of $126.1K across 55 shipments. Their average shipment value of $2.3K is below the market average of $4.6K, reflecting a high-volume, competitive pricing strategy.
VAMA LIFECARE PRIVATE LIMITED serves 5 named buyers in our database. AS PER INVOICE BRAZIL is the dominant customer, accounting for 89.0% of this supplier's tracked business. Top customers include:
• AS PER INVOICE BRAZIL — $112.2K across 49 shipments (89.0% of this supplier's total exports)
• AS PER INVOICE AS — $4.9K across 2 shipments (3.9% of this supplier's total exports)
• AS PER INVOICE — $3.8K across 2 shipments (3.0% of this supplier's total exports)
• EXP CODE — $2.6K across 1 shipments (2.1% of this supplier's total exports)
• TO THE — $2.5K across 1 shipments (2.0% of this supplier's total exports)
Key Insight: VAMA LIFECARE PRIVATE LIMITED operates with high shipment frequency (55 shipments) at a per-shipment value of $2.3K, indicating a broad distribution network with many smaller, regular orders.
5R B INTERNATIONAL
R B INTERNATIONAL is the fifth-largest Ustekinumab exporter from India, with a market share of 5.9% and a total export value of $74.6K across 14 shipments. Their average shipment value of $5.3K is above the market average of $4.6K, suggesting premium or bulk contract pricing.
R B INTERNATIONAL serves 2 named buyers in our database. NA is the dominant customer, accounting for 87.7% of this supplier's tracked business. Top customers include:
• NA — $65.4K across 12 shipments (87.7% of this supplier's total exports)
• EDUARDO HENRIQUE OSO — $9.2K across 2 shipments (12.3% of this supplier's total exports)
Key Insight: R B INTERNATIONAL's per-shipment value of $5.3K is 15% above the market average of $4.6K, consistent with large-order contracts or value-added formulations.
6AMERICAN MIDDLE EASTERN MEDICAL SOLUTIONS PRIVATE
AMERICAN MIDDLE EASTERN MEDICAL SOLUTIONS PRIVATE is the fifth-largest Ustekinumab exporter from India, with a market share of 4.5% and a total export value of $57.9K across 7 shipments. Their average shipment value of $8.3K is above the market average of $4.6K, suggesting premium or bulk contract pricing.
AMERICAN MIDDLE EASTERN MEDICAL SOLUTIONS PRIVATE serves 2 named buyers in our database. TO THE ORDER OF is the dominant customer, accounting for 76.6% of this supplier's tracked business. Top customers include:
• TO THE ORDER OF — $44.3K across 5 shipments (76.6% of this supplier's total exports)
• KING ABDUL AZIZ MEDI — $13.6K across 2 shipments (23.4% of this supplier's total exports)
Key Insight: AMERICAN MIDDLE EASTERN MEDICAL SOLUTIONS PRIVATE's per-shipment value of $8.3K is 79% above the market average of $4.6K, consistent with large-order contracts or value-added formulations.
From Indian Factories to Global Pharmacies — How Ustekinumab Flows
Once Ustekinumab leaves the manufacturing plants of companies like GNH INDIA PHARMACEUTICALS LIMITED and BIOCON BIOLOGICS INDIA LIMITED, it travels to 5 destination markets with a combined import value of $1.3M. Brazil absorbs the largest share at 71.5% ($909.9K), followed by Japan (12.6%) and Saudi Arabia (9.9%).
In Brazil — the top destination — named importers include AS PER INVOICE BRAZIL, TO THE CONCERN PERSON, NEUSA ALVES DA SILVA. In Japan, key buyers are SHIMA HIROMI.
This geographic spread reflects Ustekinumab's role as an essential active pharmaceutical ingredient (API) and finished dosage form — sourced primarily from India due to its cost-competitive, WHO-compliant manufacturing base. The Sankey diagram below maps these destination countries to their named importers in detail.
🌍 Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Where Does Ustekinumab Go? Top Importing Countries & Their Buyers
Trade flow of Ustekinumab exports from India — top destination countries and the named companies importing it
Geographic Market Flow Analysis
Top Countries → Global Importers
Market Analysis: Top Importing Countries & Their Importers
1Brazil
Brazil ranks as the first-largest destination for Ustekinumab imports from India, with a total trade value of $909.9K across 77 shipments — representing a 71.5% share of all Ustekinumab exports. The average shipment value of $11.8K is above the global average of $4.6K, indicating high-value procurement contracts or branded formulations. This market is served by 7 tracked buyers.
Named Ustekinumab importers in Brazil: AS PER INVOICE BRAZIL is the largest buyer, accounting for 12.3% ($112.2K) of this market's total imports.
• AS PER INVOICE BRAZIL — $112.2K (12.3% of Brazil's total)
• TO THE CONCERN PERSON — $56.2K (6.2% of Brazil's total)
• NEUSA ALVES DA SILVA — $29.7K (3.3% of Brazil's total)
Key Insight: Brazil's per-shipment average of $11.8K (156% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Brazil is a key market for Ustekinumab imports from India.
2Japan
Japan ranks as the second-largest destination for Ustekinumab imports from India, with a total trade value of $160.7K across 2 shipments — representing a 12.6% share of all Ustekinumab exports. The average shipment value of $80.3K is above the global average of $4.6K, indicating high-value procurement contracts or branded formulations. This market is served by 1 tracked buyer.
Named Ustekinumab importers in Japan: SHIMA HIROMI is the largest buyer, accounting for 65.8% ($105.7K) of this market's total imports.
• SHIMA HIROMI — $105.7K (65.8% of Japan's total)
Key Insight: Japan's per-shipment average of $80.3K (1642% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Japan is a key market for Ustekinumab imports from India.
3Saudi Arabia
Saudi Arabia ranks as the third-largest destination for Ustekinumab imports from India, with a total trade value of $125.8K across 2 shipments — representing a 9.9% share of all Ustekinumab exports. The average shipment value of $62.9K is above the global average of $4.6K, indicating high-value procurement contracts or branded formulations. This market is served by 1 tracked buyer.
Named Ustekinumab importers in Saudi Arabia: TO THE CONSIGNEE- is the largest buyer, accounting for 37.0% ($46.6K) of this market's total imports.
• TO THE CONSIGNEE- — $46.6K (37.0% of Saudi Arabia's total)
Key Insight: Saudi Arabia's per-shipment average of $62.9K (1264% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Saudi Arabia is a key market for Ustekinumab imports from India.
4Turkey
Turkey ranks as the fourth-largest destination for Ustekinumab imports from India, with a total trade value of $36.9K across 3 shipments — representing a 2.9% share of all Ustekinumab exports. The average shipment value of $12.3K is above the global average of $4.6K, indicating high-value procurement contracts or branded formulations. This market is served by 1 tracked buyer.
Named Ustekinumab importers in Turkey: IMPORT MANAGER INTERNATIONAL SALES CO is the largest buyer, accounting for 59.8% ($22.1K) of this market's total imports.
• IMPORT MANAGER INTERNATIONAL SALES CO — $22.1K (59.8% of Turkey's total)
Key Insight: Turkey's per-shipment average of $12.3K (167% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Turkey is a key market for Ustekinumab imports from India.
5United Arab Emirates
United Arab Emirates ranks as the fifth-largest destination for Ustekinumab imports from India, with a total trade value of $19.1K across 3 shipments — representing a 1.5% share of all Ustekinumab exports. The average shipment value of $6.4K is above the global average of $4.6K, indicating high-value procurement contracts or branded formulations. This market is served by 1 tracked buyer.
Named Ustekinumab importers in United Arab Emirates: DAWAA DRUG STORE LLC is the largest buyer, accounting for 93.8% ($17.9K) of this market's total imports.
• DAWAA DRUG STORE LLC — $17.9K (93.8% of United Arab Emirates's total)
Key Insight: United Arab Emirates's per-shipment average of $6.4K (38% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
United Arab Emirates is a key market for Ustekinumab imports from India.
People Also Ask — Ustekinumab Supplier & Trade Network
Who are the top suppliers of Ustekinumab from India?+
Which companies buy Ustekinumab from Indian manufacturers?+
Where does Ustekinumab exported from India go?+
What is the market share of the top Ustekinumab supplier from India?+
What is the average shipment value for Ustekinumab exports from India?+
Is Ustekinumab manufactured in India and exported globally?+
Which country imports the most Ustekinumab from India?+
Who are the buyers of Ustekinumab in Japan?+
How concentrated is the Ustekinumab supplier market in India?+
How do I find verified buyers for Ustekinumab in specific countries?+
Ustekinumab Trade Network — Key Takeaways
- 1GNH INDIA PHARMACEUTICALS LIMITED is India's dominant Ustekinumab exporter with a 15.4% market share and $196.0K in total exports — making it the single most important sourcing entity in this market.
- 2The top 23 suppliers collectively account for 59.1% of all tracked Ustekinumab exports, with a combined trade value of $1.3M.
- 3Brazil is the largest destination market, absorbing 71.5% of India's Ustekinumab exports ($909.9K). Japan (12.6%) and Saudi Arabia (9.9%) follow.
- 4With 276 total shipments averaging $4.6K each, the Ustekinumab export trade from India reflects both bulk API supply and finished dosage form distribution.
- 5Verified buyers across the network include SHIMA HIROMI, XXSHIXXO IXX, TO THE CONCERN PERSON, NEUSA ALVES DA SILVA — representing a diverse base of pharmaceutical importers, distributors, and generic drug manufacturers globally.
Network Overview
Supplier Network
Country Network
Network Insights
Top supplier: 5 customers
6 suppliers → 10 countries
Network value: $1.3M
Related Analysis
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ustekinumab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Network Construction: Supplier-to-buyer trade relationships constructed from verified shipment pairs in Indian Customs (DGFT) records for Ustekinumab.
- 2.Flow Mapping: 23 Indian manufacturers mapped to their international buyer networks using consignee name normalization.
- 3.Value Aggregation: Trade value per supplier-buyer link aggregated from 276 individual shipment records. Values are FOB in USD.
- 4.Geographic Clustering: Buyer networks clustered across 10 destination countries to identify geographic concentration patterns.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
276 Verified Shipments
23 manufacturers in network
Expert-Reviewed
By pharmaceutical trade specialists